Cangrelor administration in AMI-CS patients was feasible and safe with low thromboembolic rates, although hemorrhagic complications were more frequent than thrombotic events.
Is cangrelor administration feasible and safe in patients with acute myocardial infarction complicated by cardiogenic shock?
Cangrelor appears feasible and safe in AMI-CS patients, though bleeding risks are more frequent than thrombotic events and optimal dosing remains unclear.
Absolute Event Rate: 0% vs 0%
Cangrelor administration in AMI-CS patients was feasible and safe with a low rate of thromboembolic complications. Haemorrhagic complications were more frequent than thrombotic events. Nevertheless, to date, the optimal dosage of cangrelor in this clinical context still remains not universally recognized.
Ursoleo et al. (Sat,) reported a other. Cangrelor administration in AMI-CS patients was feasible and safe with low thromboembolic rates, although hemorrhagic complications were more frequent than thrombotic events.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: